AUTL

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Autolus Therapeutics Ltd

NASDAQ | AUTL

1.66

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$457.76M

Market Cap

-

P/E Ratio

-0.87

EPS

$5.00

52 Week High

$1.10

52 Week Low

HEALTHCARE

Sector

AUTL Chart

Recent Chart
Price Action

AUTL Technicals

Tags:

AUTL Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $10M
Cost Of Revenue $11M
Costof Goods And Services Sold $11M
Operating Income -$241M
Selling General And Administrative $101M
Research And Development $138M
Operating Expenses $240M
Investment Income Net -
Net Interest Income $23M
Interest Income $32M
Interest Expense $9.3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $7.7M
Income Before Tax -$219M
Income Tax Expense $1.5M
Interest And Debt Expense -
Net Income From Continuing Operations -$221M
Comprehensive Income Net Of Tax -
Ebit -$241M
Ebitda -$233M
Net Income -$221M

Revenue & Profitability

Earnings Performance

AUTL Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $783M
Total Current Assets $661M
Cash And Cash Equivalents At Carrying Value $227M
Cash And Short Term Investments $227M
Inventory $4.1M
Current Net Receivables $47M
Total Non Current Assets $122M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $12M
Intangible Assets Excluding Goodwill $12M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $361M
Other Current Assets $21M
Other Non Current Assets -
Total Liabilities $355M
Total Current Liabilities $61M
Current Accounts Payable $2M
Deferred Revenue -
Current Debt -
Short Term Debt $3M
Total Non Current Liabilities $295M
Capital Lease Obligations $53M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $297M
Other Current Liabilities $52M
Other Non Current Liabilities $245M
Total Shareholder Equity $427M
Treasury Stock -
Retained Earnings -$1.1B
Common Stock $12K
Common Stock Shares Outstanding $255M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$206M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $7.7M
Capital Expenditures $35M
Change In Receivables -
Change In Inventory -$4.2M
Profit Loss -
Cashflow From Investment -$395M
Cashflow From Financing $590M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$221M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $10M
Cost Of Revenue $11M
Costof Goods And Services Sold $11M
Operating Income -$241M
Selling General And Administrative $101M
Research And Development $138M
Operating Expenses $240M
Investment Income Net -
Net Interest Income $23M
Interest Income $32M
Interest Expense $9.3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $7.7M
Income Before Tax -$219M
Income Tax Expense $1.5M
Interest And Debt Expense -
Net Income From Continuing Operations -$221M
Comprehensive Income Net Of Tax -
Ebit -$241M
Ebitda -$233M
Net Income -$221M

AUTL News

AUTL Profile

Autolus Therapeutics Ltd Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Autolus Therapeutics Ltd is a London-based clinical-stage biopharmaceutical company dedicated to the development of cutting-edge T-cell therapies for cancer treatment. The company boasts a strong pipeline of proprietary technologies aimed at improving the safety and efficacy of cellular immunotherapies. With its innovative approach to harnessing T-cell capabilities, Autolus is strategically positioned to address significant unmet medical needs in oncology, making it a compelling prospect for institutional investors focused on advancements in cancer care.

VHAI
-20.00%
$0.00
VIVK
+4.67%
$0.30
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
RXRX
-7.21%
$6.29
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
IVF
+153.11%
$1.90
PLUG
-8.70%
$3.51
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
YDKG
-54.14%
$0.08
NVTS
+2.73%
$15.57
BYND
-22.39%
$0.52
DNN
-2.83%
$3.08
RGTI
-12.76%
$49.15
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
-20.41%
$0.56
F
-0.27%
$11.72
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
KVUE
-13.43%
$14.07
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
DFLI
-32.52%
$1.32
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
ETHD
+4.23%
$3.94
RIG
-3.00%
$3.21
MARA
-11.62%
$20.18
CLF
-3.39%
$13.47
GNPX
-43.15%
$0.47
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
VSEE
-8.56%
$0.54
BTBT
-8.99%
$3.69
AAL
-6.00%
$11.75
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
NAK
-14.20%
$2.26
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
CIFR
-10.48%
$18.82
RGTZ
+30.51%
$11.35
CRML
-13.96%
$19.54
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
MASK
+18.73%
$0.57
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
SNAP
-2.46%
$7.71
RR
-6.38%
$5.76
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
GPUS
-6.53%
$0.36
PLTR
-0.74%
$178.28
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
WULF
-9.53%
$13.99
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
PFE
-0.59%
$24.24
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
JBLU
-4.94%
$4.70
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
BMNR
-4.71%
$51.26
SATL
-27.65%
$2.99
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
-6.45%
$16.58
VHAI
-20.00%
$0.00
VIVK
+4.67%
$0.30
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
RXRX
-7.21%
$6.29
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
IVF
+153.11%
$1.90
PLUG
-8.70%
$3.51
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
YDKG
-54.14%
$0.08
NVTS
+2.73%
$15.57
BYND
-22.39%
$0.52
DNN
-2.83%
$3.08
RGTI
-12.76%
$49.15
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
-20.41%
$0.56
F
-0.27%
$11.72
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
KVUE
-13.43%
$14.07
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
DFLI
-32.52%
$1.32
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
ETHD
+4.23%
$3.94
RIG
-3.00%
$3.21
MARA
-11.62%
$20.18
CLF
-3.39%
$13.47
GNPX
-43.15%
$0.47
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
VSEE
-8.56%
$0.54
BTBT
-8.99%
$3.69
AAL
-6.00%
$11.75
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
NAK
-14.20%
$2.26
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
CIFR
-10.48%
$18.82
RGTZ
+30.51%
$11.35
CRML
-13.96%
$19.54
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
MASK
+18.73%
$0.57
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
SNAP
-2.46%
$7.71
RR
-6.38%
$5.76
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
GPUS
-6.53%
$0.36
PLTR
-0.74%
$178.28
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
WULF
-9.53%
$13.99
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
PFE
-0.59%
$24.24
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
JBLU
-4.94%
$4.70
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
BMNR
-4.71%
$51.26
SATL
-27.65%
$2.99
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
-6.45%
$16.58
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.